Anson Funds Management Lp Disclosed New Celsion Corp Position

July 17, 2017 - By Migdalia James

 Anson Funds Management Lp Disclosed New Celsion Corp Position

Investors sentiment increased to 1.22 in 2016 Q4. Its up 0.40, from 0.82 in 2016Q3. It is positive, as 9 investors sold Celsion Corporation shares while 0 reduced holdings. 3 funds opened positions while 8 raised stakes. 4.88 million shares or 46.85% more from 3.32 million shares in 2016Q3 were reported.

Vanguard Group reported 575,889 shares or 0% of all its holdings. Blackrock Inc reported 0% stake. Focused Wealth Management Inc holds 11 shares or 0% of its portfolio. 657,890 are held by Anson Funds Mngmt L P. Morgan Stanley reported 5,477 shares. Moreover, Kcg has 0% invested in Celsion Corporation (NASDAQ:CLSN) for 150,626 shares. Northern Tru reported 28,027 shares. Retail Bank Of Ny Mellon Corp reported 0% in Celsion Corporation (NASDAQ:CLSN). Deutsche Bankshares Ag reported 0% stake. Guggenheim Cap Limited Liability has 15,286 shares. Blackrock Investment Ltd Liability Corporation has invested 0% in Celsion Corporation (NASDAQ:CLSN). Creative Planning holds 16,806 shares or 0% of its portfolio. Manufacturers Life Insur Com The holds 0% or 421 shares. Renaissance Technologies Ltd Liability holds 0% or 684,798 shares. First Manhattan holds 0% or 4 shares.

The New Anson Funds Management Lp Holding in Celsion Corp

Anson Funds Management Lp reported SC 13G form with the SEC for Celsion Corp. Access it here: 000119312517229357. As reported by Anson Funds Management Lp, the filler owns 9.6% or 760,000 shares of the Health Care–company.

Celsion Corp stake is new for [reportingPerson]. Date of activity: July 06, 2017. This shows Anson Funds Management Lp’s positive view for Celsion Corp. For a institutional investor managing $326.98 million in assets and having 5+ experts this is interesting position.

Celsion Corp Institutional Sentiment

Filings show 32 investors own Celsion Corp. The ownership in Q3 2015 is low, at 173.39 % of the outstanding shares. This is increased by 2827313. 7056897 were owned by these investors. 4 funds opened new Celsion Corp stakes, 9 increased positions. There were 9 that closed positions and 8 reduced them.

Carroll Financial Associates Inc is an investor bullish on Celsion Corp, owning 563 shares as of Q3 2015 for less than 0.01% of its portfolio. Focused Wealth Management Inc owns 11 shares or less than 0.01% of its portfolio. PA Riggs Asset Managment Company have less than 0.01% of its portfolio for 29 shares. Further, Sabby Management Llc reported stake worth 0.01% of its portfolio. The IL Perritt Capital Management Inc owns 200000 shares. Celsion Corp is 0.07% of its portfolio.

Business Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

SEC Form 13G.

Anson Funds Management Lp website.

The stock increased 2.20% or $0.04 on July 17, reaching $1.86. About 187,397 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since July 17, 2016 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation is an oncology drug development company. The company has market cap of $7.41 million. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). It currently has negative earnings. The Company’s pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

More notable recent Celsion Corporation (NASDAQ:CLSN) news were published by: Globenewswire.com which released: “Celsion Corporation Announces $5 Million Registered Direct Offering” on July 06, 2017, also Globenewswire.com with their article: “Celsion Corporation Announces Cancellation of Registered Direct Offering” published on June 22, 2017, Globenewswire.com published: “Celsion Corporation Announces $5.4 Million Registered Direct Offering” on June 19, 2017. More interesting news about Celsion Corporation (NASDAQ:CLSN) were released by: Reuters.com and their article: “BRIEF-Celsion Corp agreed to sell about 2.435 million shares of common stock” published on July 06, 2017 as well as Seekingalpha.com‘s news article titled: “Celsion Carves Itself A New Path” with publication date: July 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.